Ranbaxy rise 3% on ulcer drug launch

Ranbaxy Laboratories gained over 3 per cent after the pharmaceutical major announced the launch of a generic version of an ulcer pill Prilosec in the United States under an agreement with AstraZeneca. Omeprazole is the generic name of Prilosec. Prilosec 40 mg had sales of $204.2 million in the US market, Ranbaxy said in a statement citing IMS March 2008 data.